文献速递肾小球疾病慢性肾脏病

利妥昔单抗治疗PLA2R相关膜性肾病合并严重CKD

Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
PubMed 文献 · Kidney Int Rep · 2019-12-20

该回顾性研究纳入13例PLA2R相关膜性肾病合并4或5期CKD患者,共接受14次利妥昔单抗治疗。中位随访40.8个月后,10次治疗使eGFR升高并肾病综合征缓解,4次治疗失败需慢性血透;免疫学缓解与良好临床结局相关,3例发生严重不良事件。

要点

  • 利妥昔单抗在PLA2R相关膜性肾病合并4/5期CKD中可能有效且较安全。
  • 免疫学缓解与临床缓解相关,治疗前尿白蛋白/蛋白比值可预测肾脏反应。
  • 部分患者仍失败需透析,需警惕严重不良事件。

核心结论

  • 利妥昔单抗在PLA2R相关膜性肾病合并4或5期CKD患者中似乎有效且安全性可接受。
  • 免疫学缓解与良好临床结局相关。

研究设计与样本

  • 回顾性研究,纳入13例PLA2R相关膜性肾病合并4或5期CKD患者,2012年1月至2018年3月共接受14次连续利妥昔单抗治疗。
  • 治疗方案为每周2次375 mg/m2输注或间隔两周的2次1 g/d输注,必要时重复以达到免疫学缓解。

主要发现

  • 首次利妥昔单抗输注时平均eGFR为18 ± 7 ml/min per 1.73 m2,血清白蛋白为25.2 ± 5.4 g/l,尿蛋白为13.2 ± 7.5 g/d,所有患者血清PLA2R抗体阳性。
  • 中位随访40.8个月(四分位距14.8-46.8)后,10次治疗导致eGFR升高和肾病综合征缓解。
  • 4次利妥昔单抗治疗失败,患者1年内需慢性血液透析。
  • 治疗前尿白蛋白/蛋白比值可预测肾脏反应。
  • 11次治疗课程后发生免疫学缓解,其中10例与临床反应相关。

临床怎么用

  • 对PLA2R相关膜性肾病合并4或5期CKD患者,可考虑利妥昔单抗治疗并监测免疫学缓解。
  • 治疗前尿白蛋白/蛋白比值可能有助于预测肾脏反应。

局限性

  • 回顾性研究,样本量小(13例患者,14次治疗)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)-associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membranous nephropathy. Whether its use is also appropriate in patients with an estimated glomerular filtration rate <30 ml/min per 1.73 m2 has not been investigated. METHODS: We retrospectively reviewed characteristics and outcome of 13 patients with PLA2R-associated membranous nephropathy and stage 4 or 5 chronic kidney disease who received a total of 14 consecutive RTX treatments from January 2012 to March 2018. The treatment regimen consisted of either 2 weekly infusions of 375 mg/m2 or 2 RTX infusions of 1 g/d two weeks apart. When needed, the regimen was repeated to achieve immunological remission. RESULTS: The mean estimated glomerular filtration rate, serum albumin level, and urinary protein level at the first RTX infusion were 18 ± 7 ml/min per 1.73 m2, 25.2 ± 5.4 g/l, and 13.2 ± 7.5 g/d, respectively, with all patients being tested positive for serum PLA2R antibodies. Ten treatment courses led to an increase in estimated glomerular filtration rate and remission of nephrotic syndrome after a median follow-up of 40.8 months (interquartile range, 14.8-46.8). Conversely, 4 RTX treatments were unsuccessful, with patients requiring chronic hemodialysis within 1 year. The urinary albumin-to-protein ratio before treatment was predictive of renal response. Immunological remission occurred after 11 treatment courses and was associated with clinical response in 10 of 11 patients. Three patients experienced severe adverse events. CONCLUSION: RTX seems effective and reasonably safe in PLA2R-associated membranous nephropathy with stage 4 or 5 chronic kidney disease. Immunological remission is associated with a good clinical outcome.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Hanset N, Esteve E, Plaisier E, et al. Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD. Kidney Int Rep. 2019. PMID: 32154454. doi:10.1016/j.ekir.2019.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。